secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0001193125-22-207791
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex presents pepinemab AD/HD data at AAIC 2022; SIGNAL-AD first patient completed with no safety concerns
--------------------------------------------------------------------------------

- Presented poster at AAIC 2022 on pepinemab (SEMA4D antibody) for Alzheimer's and Huntington's disease.
- Phase 2 HD study showed pepinemab restored learning and increased brain metabolic activity (FDG-PET).
- Ongoing Phase 1/2a SIGNAL-AD study: first patient completed with no safety concerns as of Q2 2022.
- Pepinemab targets glial activation to reduce neuroinflammation; funded by Alzheimer's Association and ADDF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522207791/0001193125-22-207791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522207791/d340607d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-207791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer